Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 22,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Completed No phase listed Observational

Circulating Tumor Cells in Operative Blood

NCT02150746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Peripheral/Central Venous Blood Draw, Peritoneal Wash
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 23, 2026, 5:51 AM EDT
Recruiting Phase 1 Interventional

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

NCT07878988
View directory record Official record
Conditions
Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer
Interventions
LTZ-232
Drug
Lead sponsor
LTZ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed No phase listed Observational

Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study

NCT05591703
View directory record Official record
Conditions
Opioid Use Disorder, Relapse
Interventions
Clinical Outcomes and Questionnaires
Behavioral
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Rancho Mirage, California • Center City, Minnesota • Plymouth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

NCT01170897
View directory record Official record
Conditions
Solid Tumor
Interventions
PEGPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Encinitas, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Targeting IL-17A for Treatment-Resistant Depression

NCT04979910
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ixekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

NCT00230282
View directory record Official record
Conditions
Leukemia, B-cell Leukemia, Chronic Leukemia, Chronic Lymphocytic Leukemia (CLL)
Interventions
Alemtuzumab, Fludarabine, Cytoxan
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 23, 2026, 5:51 AM EDT
Not yet recruiting Phase 2 Interventional

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

NCT07672782
View directory record Official record
Conditions
Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
Interventions
Tisotumab Vedotin
Drug
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Recruiting Phase 1 Interventional

Hydrogen's Feasibility and Safety as a Therapy in ECPR

NCT05574296
View directory record Official record
Conditions
Cardiac Arrest, Extracorporeal Membrane Oxygenation, Reperfusion Injury
Interventions
Hydrogen, Usual care
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 23, 2026, 5:51 AM EDT
Terminated Phase 2 Interventional Results available

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562
View directory record Official record
Conditions
Infections, Intestinal
Interventions
Drug: GSK2251052, Meropenem, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

NCT00402246
View directory record Official record
Conditions
Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
Interventions
Remote Management, In-Office Care
Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
127
States / cities
Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 23, 2026, 5:51 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288
View directory record Official record
Conditions
Advanced ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

NCT00968227
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Vasospasm
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

NCT01428713
View directory record Official record
Conditions
Menorrhagia
Interventions
Oral tranexamic acid, Oral Contraceptive Pills
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

NCT00742859
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
betrixaban, Warfarin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 23, 2026, 5:51 AM EDT
Not listed Phase 1 Interventional

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

NCT01165762
View directory record Official record
Conditions
ESRD
Interventions
Immune Tolerance
Drug
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 5:51 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

NCT03273062
View directory record Official record
Conditions
Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions
Tolcapone 200 MG, Placebo
Drug · Other
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 23, 2026, 5:51 AM EDT
Completed No phase listed Observational

The Experience of Uncertainty in Parents of Children With an Undiagnosed Medical Condition

NCT00955370
View directory record Official record
Conditions
Multiple Abnormalities
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

NCT00781573
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 23, 2026, 5:51 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Cryotherapy for GAVE

NCT04760873
View directory record Official record
Conditions
GAVE - Gastric Antral Vascular Ectasia, Bleeding, Bleeding Gastric
Interventions
cryotherapy
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
5
States / cities
Tampa, Florida • New Hyde Park, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

NCT00496873
View directory record Official record
Conditions
Lymphoma
Interventions
Cytoxan, Nipent, Rituxan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 4 Interventional

A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.

NCT05843669
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
Guafenesin tablets
Drug
Lead sponsor
American Health Research
Other
Eligibility
40 Years to 90 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Charlotte, North Carolina • Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

NCT00046683
View directory record Official record
Conditions
B Cell Chronic Lymphocytic Leukemia
Interventions
alemtuzumab
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 23, 2026, 5:51 AM EDT
Recruiting Phase 2 Interventional

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
inhaled mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

NCT03257410
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Theranova 400 dialyzer, Elisio-17H dialyzer
Device
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Corona, California • Riverside, California • Bloomfield, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 23, 2026, 5:51 AM EDT